Abstract: The present disclosure relates to synthetic oncolytic viruses comprising a lipid nanoparticle comprising one or more types of lipid and a self-amplifying replicon RNA comprising a sequence that encodes an immunomodulatory molecule.
Type:
Grant
Filed:
June 14, 2023
Date of Patent:
August 12, 2025
Assignees:
Massachusetts Institute of Technology, Ohio State Innovation Foundation
Inventors:
Darrell J. Irvine, Karl Dane Wittrup, Ron Weiss, Yingzhong Li, Noor Momin, Yizhou Dong
Abstract: The present disclosure provides methods for utilizing genetically modified microbes to co-produce 3-hydroxypropionic acid (3-HP) and acetyl-CoA, and derivatives thereof from malonate semialdehyde as a common single intermediate. The disclosure further provides modified microbe that co-produce the 3-HP and acetyl-CoA derivatives from malonate semialdehyde.
Type:
Grant
Filed:
July 1, 2022
Date of Patent:
August 5, 2025
Assignee:
Braskem S.A.
Inventors:
Beatriz Leite Magalhaes, Paulo Moises Raduan Alexandrino, Felipe Galzerani
Abstract: The present invention provides a nanodisc with a membrane scaffold protein. The nanodisc includes a membrane scaffold protein, a telodendrimer and a lipid. The membrane scaffold protein can be apolipoprotein. The telodendrimer has the general formula PEG-L-D-(R)n, wherein D is a dendritic polymer; L is a bond or a linker linked to the focal point group of the dendritic polymer; each PEG is a poly(ethylene glycol) polymer; each R is and end group of the dendritic polymer, or and end group with a covalently bound hydrophobic group, hydrophilic group, amphiphilic compound, or drug; and subscript n is an integer from 2 to 20. Cell free methods of making the nanodiscs are also provided.
Type:
Grant
Filed:
June 13, 2023
Date of Patent:
July 29, 2025
Assignee:
LAWRENCE LIVERMORE NATIONAL SECURITY, LLC
Inventors:
Juntao Luo, Wei He, Kit S. Lam, Paul Henderson, Matthew A. Coleman
Abstract: Glycan-binding proteins, and compositions thereof, are generally described, including methods of making and using such proteins. The proteins may include scaffolds based on easily evolvable DNA-binding proteins, with binding sites able to specifically bind to mono- or disaccharides, such as monosaccharide-binding determinants, disaccharide-binding determinants, more complex carbohydrates, etc. In certain aspects, a protein may be generated starting from a small DNA-binding protein, such as Sso7d. Such glycan-binding proteins may have numerous applications, including in enzyme-linked immunosorbent assays (ELISAs), glycan characterization, cell selection, flow cytometry, histology, imaging, arrays, affinity purification, enzyme-linked visualization, binding to a target for pharmaceutical purposes, etc.
Type:
Grant
Filed:
January 26, 2023
Date of Patent:
July 29, 2025
Assignee:
Massachusetts Institute of Technology
Inventors:
Barbara Imperiali, Cristina Zamora, Elizabeth Ward
Abstract: The present disclosure relates to antibodies specifically binding to CD147 or antigen-binding fragment thereof, and a method of treating a disease or condition in a subject in need thereof, comprising administering to the subject an anti-CD147 antibody or antigen-binding fragment, or a polynucleotide encoding the anti-CD147 antibody or antigen-binding fragment, or a pharmaceutical composition comprising the anti-CD147 antibody or antigen-binding fragment or the polynucleotide; use of the anti-CD147 antibody or antigen-binding fragment thereof, or the polynucleotide in the manufacture of a pharmaceutical or kit for treating a disease or condition; as well as of use the combination of the anti-CD147 antibody or antigen-binding fragment thereof, or the polynucleotide, and a MCT inhibitor in the manufacture of a pharmaceutical or a kit for treating a disease or condition.
Abstract: The present specification provides a monoclonal antibody that specifically binds aggregated, non-phosphorylated ?-synuclein and a hybridoma producing it. Also disclosed are methods of generating antibodies that specifically binds aggregated, non-phosphorylated ?-synuclein and uses thereof. Uses of anti-?-synuclein antibody in detection and diagnostic assays, and for prophylaxis or therapy of ?-synuclein-associated neurodegenerative diseases, are also disclosed.
Abstract: Provided herein are methods and compositions for purifying antibodies. Purification is achieved by increasing the binding capacity of protein A chromatography by covalent attachment of a protein A domain (E, D, A, B, C), or domain Z, or a functional variant thereof, to Drosophila melanogaster transcription factor Ultrabithorax (Ubx) materials. The compositions include fusion proteins containing Drosophila melanogaster transcription factor Ultrabithorax (Ubx) or a fragment thereof and an immunoglobulin binding protein. In some embodiments, the immunoglobulin binding protein is a protein A domain, a protein Z domain or a fragment thereof.
Abstract: The present invention provides engineered antibodies and antigen binding fragments, in which an additional functional domain is inserted into the elbow region of the antibody or antigen binding fragment. The present invention also provides nucleic acid molecules, such as vectors, encoding such antibodies and antigen binding fragments, host cells and compositions comprising such antibodies, antigen binding fragments or nucleic acid molecules and uses thereof. For example a multispecific antibody format is provided, in which an additional binding site (specificity) is inserted into the elbow region of an antibody or antigen binding fragment.
Abstract: The invention relates generally to multispecific polypeptides having constrained CD3 binding. In some embodiments, components of the multispecific polypeptides are connected by a non-cleavable linker. Also provided are methods of making and using these multispecific polypeptides in a variety of therapeutic, diagnostic and prophylactic indications.
Type:
Grant
Filed:
June 6, 2023
Date of Patent:
June 17, 2025
Assignee:
Inhibrx Biosciences, Inc.
Inventors:
Brendan P. Eckelman, Michael D. Kaplan, Katelyn M. Willis, John C. Timmer
Abstract: Provided are multi-specific antibodies that target both a cellular efflux pump and a cancer-associated antigen as well as pharmaceutical compositions, nucleic acids, recombinant expression vectors, cells, and kits that include or encode such multi-specific antibodies. Methods of treating a subject for a cancer that include administering to the subject a multi-specific antibody that targets both a cellular efflux pump and a cancer-associated antigen are also provided. Provided as well are methods of generating the described multi-specific antibodies and reagents related thereto, including genetically modified cell lines useful in the subject methods and methods of making such genetically modified cell lines.
Type:
Grant
Filed:
April 1, 2020
Date of Patent:
June 17, 2025
Assignee:
William Robert Arathoon Living Trust Dated August 29, 2016
Inventors:
William Robert Arathoon, Evan Matthew Bishop, Raffaella Briante, Alissa Loren Briggs, Suchismita Mohanty, Paul David Ponath, Cindy Tan, Qianting Zhai
Abstract: Provided are nucleic acid molecules, including vectors and plasmids, encoding modified u-PA polypeptides and fusion proteins containing the modified u-PA polypeptides. The u-PA polypeptides are modified to have altered activity and/or specificity so that they cleave a complement protein, such as complement protein C3, to thereby inhibit complement activation. The nucleic acids and encoded modified u-PA polypeptides and fusion proteins that inhibit complement activation can be used for treatment of diseases and conditions that are mediated by complement activation, or in which complement activation plays a role. These disorders include ischemic and reperfusion disorders, including myocardial infarction and stroke, sepsis, autoimmune diseases, diabetic retinopathies, age-related macular degeneration, transplanted organ rejection, inflammatory diseases and diseases with an inflammatory component.
Type:
Grant
Filed:
February 10, 2023
Date of Patent:
June 17, 2025
Assignee:
Vertex Pharmaceuticals, Incorporated
Inventors:
Edwin L. Madison, Christopher Thanos, Vanessa Soros, Mikhail Popkov, Kimberly Tipton, Matthew John Traylor, Eric Steven Furfine, Jeffrey Charles Way
Abstract: Provided are an anti-TNF?/anti IL-17A natural antibody structure-like heterodimer form of a bispecific antibody and a preparation method therefor, wherein the antibody can bind two target molecules simultaneously, and can be used for treating complex diseases.
Abstract: Disclosed herein are methods, compositions and kits for the synthesis of proteins which comprises unnatural amino acids that utilize a mutant tRNA.
Type:
Grant
Filed:
October 4, 2023
Date of Patent:
June 3, 2025
Assignees:
THE SCRIPPS RESEARCH INSTITUTE, SYNTHORX, INC.
Inventors:
Jerod Ptacin, Carolina Caffaro, Hans Aerni, Yorke Zhang, Emil C. Fischer, Aaron W. Feldman, Vivian T. Dien, Floyd E. Romesberg
Abstract: The present invention provides co-formulations of anti-PD-1 antibodies and anti-LAG3 antibodies, and their use in treating various disorders.
Type:
Grant
Filed:
November 6, 2019
Date of Patent:
June 3, 2025
Assignee:
Merck Sharp & Dohme LLC
Inventors:
Valentyn Antochshuk, Preeti G. Desai, Yogita Krishnamachari, Sahil S. Sangani
Abstract: Method of detecting phosphorylation at Threonine 166 of a Rubicon protein to identify a subject having a disease associated with Leucine-rich repeat kinase 2 (LRRK2) such as Parkinson's disease and compounds and methods for treating the same.
Abstract: Glass beads which are functionalized by lysine or polylysine adsorbed on their surface, a device that includes a container that contains glass beads which are functionalized by lysine or polylysine adsorbed on their surface, and their use for capturing microorganisms. Also the diagnostic, elimination or reduction of the load of microorganisms of liquid or viscous samples in which microorganisms are captured on the glass beads which are functionalized by lysine or polylysine.
Abstract: Provided herein are formulations and drug product processes that can improve cell viability and minimize waste of the manufactured formulated cells for a drug product.
Type:
Grant
Filed:
February 3, 2022
Date of Patent:
May 13, 2025
Assignee:
Allogene Therapeutics, Inc.
Inventors:
Muneeswara Babu Medi, Zhuojin Xu, Jung S. Lee, Yajin Ni, Mark W. Leonard
Abstract: An object of the present invention is to provide a method of efficiently extracting a target protein contained in a biological sample such as serum or plasma, thereby enabling highly precise analysis. In the present invention, there is provided the method in which a protein is removed from a sample derived from a living body to extract the target protein, and a salt and/or urea at a high concentration, and a water-soluble organic solvent are used.
Abstract: Disclosed are peptides comprising a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-COV-2 antigen; and a trimerization domain. Disclosed are peptide complexes comprising three peptides, wherein each of the three peptides comprises a monomeric Fc fragment of an immunoglobulin recognized by a FcRn; SARS-COV-2 antigen; and a trimerization domain. Disclosed are compositions comprising any of the disclosed peptides or peptide complexes. Disclosed are methods for eliciting a protective immune response against SARS-COV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein. Disclosed are methods of treating a subject exposed to SARS-COV-2 or at risk of being exposed to SARS-COV-2 comprising administering to a subject an effective amount of one or more of the compositions disclosed herein.
Abstract: Described are novel anti-CTLA-4 antibody molecules and nucleotide sequences and expression vectors, such as viruses, encoding such antibody molecules. The novel antibody molecules are Treg depleting antibody molecules, and they have an improved depleting effect on CTLA-4 positive cells, such as Tregs, compared to ipilimumab. Described is also the use of such antibody molecules or nucleotide sequences or viruses in medicine, such as in the treatment of cancer, such as solid tumours.
Type:
Grant
Filed:
September 3, 2019
Date of Patent:
May 6, 2025
Assignee:
BIOINVENT INTERNATIONAL AB
Inventors:
Björn Frendéus, Ingrid Teige, Monika Semmrich, Linda Mårtensson, Petra Holmkvist